Ocular Therapeutix submits PMA for ReSure ophthalmic sealant

February 25, 2013 by Sony Salzman

Ocular Therapeutix applies for pre-market approval from the FDA CEO, hoping to win a green light for the U.S. market this year.

Ocular Therapeutix logo

There's nothing left for Ocular Therapeutix to do but sit back and wait for the FDA to decide on the pre-market approval application for its ReSure ophthalmic sealant.

The Bedford, Mass.-based medical device company is hoping to be able to get the sealant on the U.S. market this year based on a 488-patient clinical trial, CEO Amar Sawhney said in prepared remarks.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.